Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 721 to 735 of 1108 results for infections

  1. Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum antibiotic therapy, without adversely affecting outcomes?

    hospital-acquired pneumonia to guide antibiotic therapy. Hospital-acquired infections can be caused by highly resistant pathogens that...

    Research recommendation
    Published
    9 June 2015

  2. Intrapartum antibiotics: What is the clinical and cost effectiveness of intrapartum antibiotics for women with meconium-stained amniotic fluid?

    Source guidance details Comes from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195

    Research recommendation
    Published
    6 August 2021

  3. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  4. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

    HealthTech guidance
    Published
    17 February 2016
    View recommendations

    Sections for HTG401

  5. Hand decontamination:- When clean running water is not available, what is the clinical and cost effectiveness of using wipes, gels, handrubs or other products to remove visible contamination?

    guidance details Comes from guidance Healthcare-associated infections: prevention and control in primary and community care Number

    Research recommendation
    Published
    9 June 2015

  6. Curos for preventing infections when using needleless connectors (MTG44)

    We have moved Medical technologies guidance 44 to become HealthTech guidance 510. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Infracoccygeal sacropexy using mesh to repair uterine prolapse (HTG443)

    Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair uterine prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the uterus in place.

    HealthTech guidance
    Published
    28 June 2017
    View recommendations

    Sections for HTG443

  8. Education and psycho-behavioural interventions for prevention:- What is the role of educational models and psycho-behavioural interventions in prevention of diabetic foot complications?

    monitor and evaluate the rates (and recurrent rates) of foot ulceration, infection and gangrene resulting from diabetes, rates and...

    Research recommendation
    Published
    12 October 2015

  9. Intensive monitoring for people at risk of diabetic foot problems:- Does intensive monitoring of people at risk of diabetic foot disease reduce the morbidity associated with developing the disease and is such monitoring cost effective?

    The proposed study would monitor and evaluate the rates of foot ulcer or infection resulting from diabetes, rates and extent of...

    Research recommendation
    Published
    12 October 2015

  10. Headaches in over 12s: diagnosis and management (CG150)

    This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.

    Clinical guideline
    Last updated
    3 June 2025
    View recommendations

    Sections for CG150

  11. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

    Evidence summary
    Published
    25 March 2014

  12. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA174

  13. Acute hepatic encephalopathy:- In people with cirrhosis and an acute episode of hepatic encephalopathy secondary to a clearly identified, potentially reversible precipitating factor, does management of the precipitating event alone improve the hepatic encephalopathy without specific treatment?

    encephalopathy there is a clearly defined precipitating factor (for example, infections, gastrointestinal bleeding or overuse of...

    Research recommendation
    Published
    11 January 2024

  14. Ustekinumab for treating moderate to severe plaque psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  15. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA430